Urine\/creatinine was the variable with the highest importance and ID’d highest risk group when combined with urine epidermal growth factor\/creatinine<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, June 24, 2025 (HealthDay News) — A biomarker panel can improve prediction of chronic kidney disease (CKD) progression in children, according to a study published in the June issue of the Journal of the American Society of Nephrology<\/em>.<\/p>\n Jason H. Greenberg, M.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues prospectively enrolled children aged 6 months to 16 years with an estimated glomerular filtration rate (eGFR) of 30 to 90 mL\/min\/1.73 m2<\/sup>. Biomarkers were measured in stored plasma and urine collected five months after enrollment, and a regression tree-based model was constructed using a panel of clinically relevant biomarkers to predict the time to the composite event. The primary outcome was CKD progression (defined as a composite of 50 percent eGFR decline or kidney failure).<\/p>\n A total of 599 children were included; 205 (34 percent) reached the primary outcome of CKD progression. A final set of four prognosis groups were suggested using a single regression tree-based model utilizing the most informative predictors with data-driven biomarker thresholds. The researchers found that urine albumin\/creatinine was the variable with the highest importance in the final model and, together with urine epidermal growth factor\/creatinine, identified the highest risk group of 24 children, of whom 100 percent developed CKD progression at a median of 1.3 years. The C-statistic increased from 0.76 to 0.85 when the regression tree-derived risk group classifications were added to prediction models including clinical risk factors.<\/p>\n “This research could help physicians with clinical monitoring and treatment strategies for individual patients, potentially slowing disease progression and improving long-term outcomes,” Greenberg said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n